StockData

Pyxis Oncology vs Whitehawk Therapeutics

PYXS and WHWK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PYXS and WHWK compare

Whitehawk Therapeutics is the larger company, worth 1.5 times as much as Pyxis Oncology ($176M against $120M).

Whitehawk Therapeutics scores higher on the StockData Score (8 against 5 for Pyxis Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPYXSWHWK
Size and price
Market cap$120M$176M
Share price$1.44$3.08
Change, 1 year−67.0%43.9%
Change, 5 years−88.8%−86.3%
Beta (5Y)3.152.33
Employees5623
StockData Score
Total score58 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score56 (better)
Dividend score00
Valuation
P/B10.5×1.0× (better)
FCF yield–−39.5%
Growth
Revenue growth (TTM)–−100%
Revenue growth, 5Y average–−12.6%
Profitability
Return on equity−179%−45.0% (better)
Financial health
Debt / equity0.000.00
Current ratio1.3417.38 (better)
Altman Z-score−16.216.35 (better)
Piotroski F-score14 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions40.9%75.8%
Held by insiders20.4%49.9%
Insider net buying, 12 months−$107K (better)−$2.6M
Short interest, % of float6.8%8.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.